39results about How to "Deterioration progress" patented technology

Aspects of the invention provide a method of manufacturing a luminescence device including forming the first electrode on a substrate, forming a function layer including a luminescence layer on the first electrode, forming a second electrode on the function layer, and forming a sealing layer that covers a luminescence portion, formed of the first electrode, the function layer, and the second electrode, and the sealing layer is formed by an ink-jet method. Accordingly, the deterioration of a luminescence device that is sealed with the sealing layer can be prevented for a long period of time by an inexpensive method.

There is provided a biochemical reaction cartridge comprising at least one chemical reaction chamber that accommodates a solution for biochemically treating a sample, a reaction chamber for performing detection reaction of a target substance in the biochemically treated sample, and a detection reaction information fetching section for fetching information on whether or not the detection reaction is performed, wherein the biochemical reaction cartridge is provided with a covering unit that can cover and expose at least the reaction information fetching section.

A light source device includes: a light source unit including an arc tube that emits a light between a pair of electrodes, and a reflector that reflects the light coming from the arc tube for emission of a source light; and a drive control section that drives the light source unit by a predetermined driving power. In the device, the drive control section performs power regulation control of reducing the driving power of the light source unit at a predetermined timing by a predetermined amount.

The invention analyzes relationships between factors, within a patient population, to identify autonomic dysfunction patterns. Patient test results are then compared with the identified patterns to determine the patient's autonomic function. The invention can continually amend the patient population with new test results to create increasingly accurate normative data sets from which a patient's autonomic function can be more accurately assessed. The invention may apply this concept in an application service provider model. An embodiment of the invention may use a novel method of identifying ECG R-waves. The method locates R-waves by searching for maximum slope values, in signals, that exceed threshold values. Another embodiment of the invention entails a non-provocative HRV test whereby certain time domain and frequency domain factors are analyzed to determine a patient's autonomic function.

The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In (particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion in the hypoxia responsive element (HRE) of the VEGF promoter which alters the hypoxic upregulation of VEGF. These mice suffer severe adult onset muscle weakness due to progressive spinal motor neuron degeneration which is reminiscent of amyotrophic lateral sclerosis (ALS)-a fatal disorder with unknown aetiology. Furthermore, the neuropathy of these mice is not caused by vascular defects, but is due to defective VEGF-mediated survival signals to motor neurons. The present invention relates in particular to the isoform VEGF165 which stimulates survival of motor neurons via binding to neuropilin-1, a receptor known to bind semaphorin-3A which is implicated in axon retraction and neuronal death, and the VEGF Receptor-2. The present invention thus relates to the usage of VEGF, in particular VEGF165, for the treatment of neuron disorders and relates, in addition, to the usage of polymorphisms in the VEGF promotor for diagnosing the latter disorders.

A chip antiscatter mechanism is included and configured to suppress scattering of chips generated during machining of a machining object. The chip antiscatter mechanism includes chip stirring means configured to stir the chips, by jetting a gas into a dry machining region above a table including the machining object, fluid curtain forming means configured to form a fluid curtain by jetting a fluid such as liquid or gas membranously from above to an outside of the dry machining region so as to surround the dry machining region, and to form a closed region including the dry machining region by the membranous fluid curtain, and discharging means configured to receive and discharge the fluid jetted membranously by the fluid curtain forming means.

Provided is a terminal box for a solar cell module that has excellent heat radiation. The terminal box (10) is provided with multiple terminal boards (21), a reverse load bypass diode (22) that is connected to two corresponding terminal boards (21), a primary resin layer (23) that is attached to the diode (22) and covers the area around the diode (22), and a secondary resin layer (41) that is made from a resin different to that of the primary resin layer (23) and is adhered to parts other than the diode (22) and does not cover the area around the diode (22).

When a hot water supply operation is started, a single mode is used in which hot water is output only from a second hot water supply circuit of a water heater, by cut-off of a flow path in a first hot water supply circuit of a space-heating water heater by a cut-off mechanism. When a load imposed by hot water supply by the second hot water supply circuit increases during the hot water supply operation in the single mode, the cut-off mechanism is opened to start hot water output from the first hot water supply circuit and a hot water supply operation in a parallel mode is performed in which hot water is output from both of the first hot water supply circuit and the second hot water supply circuit.

A controller for a hybrid vehicle predicts whether necessary discharging electric power from a power storage device which is required to perform downshift in a transmission exceeds upper-limit discharging electric power of the power storage device when downshift in the transmission is performed in a hybrid vehicle travel mode and controls a compressor rotation speed such that a rate of increase of the compressor rotation speed of a supercharger at the time of performing downshift in the transmission increases as the upper-limit discharging electric power decreases when it is predicted that the necessary discharging electric power exceeds the upper-limit discharging electric power.

A display device includes a display configured to display a deterioration degree of a secondary battery and a controller. The controller is configured to control the display such that the display does not display the deterioration degree when the deterioration degree is lower than a first level, or configured to control the display such that the display does not display the deterioration degree when the deterioration degree is higher than a second level that is higher than the first level.

The present invention relates to a composition for prevention and treatment of kidney diseases comprising one or more effective component(s) of a PAR-2 activating agent which is able to activate PAR-2 and a pharmaceutically acceptable carrier. The present invention further relates to a method for prevention and treatment of kidney diseases comprising administration of a composition for prevention and treatment of kidney diseases containing a PAR-2 activating agent which is able to activate PAR-2 to patients suffering from kidney diseases, and also relates to the use of a PAR-2 activating agent which is able to activate PAR-2 for the manufacture of a composition for prevention and treatment of kidney diseases. The present invention furthermore relates to a method for screening an effective ingredient for prevention and treatment of kidney diseases comprising screening of the activating action of the test substance to PAR-2.

Treating or preventing degeneration or destruction of articular cartilage and/or subchondral bone in the affected joint of a mammal is accomplished by administering a compound of formula (I), wherein the variables have the meanings given in the present description. A preferred compound of formula (I) is formula (II). This treatment ameliorates, diminishes, actively treats, reverses or prevents any injury, damage or loss of articular cartilage or subchondral bone subsequent to said early stage of said degeneration.